Effects of perioperative Recombinant Human Erythropoietin administration on proinflammatory cascade following breast cancer surgery.

Phase 2

Completed

• Conditions: Female subjects with breast cancer stage II/III undergoing a modified radical mastectomy; Cancer - Breast; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12610000813088
• Lead Sponsor: niversity Hospital of Ioannina

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 22

Inclusion Criteria

The inclusion criterion was defined as an established preoperative diagnosis of breast cancer stage II or III.

Exclusion Criteria

(1) hemoglobin concentration>13gr/dl at presentation, (2) previous history of malignancy, (3) history of thromboembolic events, (4) history of seizures, (5) hypertension, (6) known allergy to Recombinant Human Erythropoietin , (7) patients with hepatic, renal, metabolic or endocrine disease, (8) patients receiving medications known to interfere with wound healing, (9) neoadjuvant chemotherapy, (11) recent major surgical procedure or recent history of transfusion and (12) patient’s denial to informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified